No Data
Hicin Pharmaceutical Jointly Invests Into 20 Million Yuan New Materials Venture
Nanjing Hicin Pharmaceutical (300584.SZ) intends to establish a joint venture to enter the Solid State Battery materials field.
Nanjing Hicin Pharmaceutical (300584.SZ) issued an announcement that its holding subsidiary, Anqing Huichen Technology Co., Ltd. (abbreviated as "...").
nanjing hicin pharmaceutical (300584.SZ): Currently not involved in AI pharmaceuticals
On November 6th, Ge Longhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) stated on the investor interaction platform that the company is currently not involved in AI pharmaceuticals.
Nanjing Hicin Pharmaceutical (300584.SZ): Approval Notice for Supplementary Drug Application for the increased specification of Landedol Hydrochloride for Injection.
On November 6, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) recently received the Approval Notification for the supplementary application of Injection Landlelol Hydrochloride issued by the National Medical Products Administration (referred to as "NMPA"), approving the addition of 150mg specification on top of the approved 50mg specification, and considering it as passing the consistency evaluation.
Nanjing Hicin Pharmaceutical (300584.SZ): Voglibose tablets pass generic drug consistency evaluation
格隆汇October 28th | nanjing hicin pharmaceutical (300584.SZ) announced that the company recently received the "Drug Supplementary Application Approval Letter" issued by the National Medical Products Administration, and Voglibose tablets passed the generic drug quality and efficacy consistency evaluation. Voglibose tablets are oral hypoglycemic drugs, belonging to α-glucosidase inhibitors, which inhibit the α-glucosidase in the intestines that decompose disaccharides into monosaccharides, thereby delaying the digestion and absorption of sugar and improving postprandial hyperglycemia. The product is mainly used to improve postprandial hyperglycemia in diabetic patients (applicable to patients who have not achieved obvious effects with diet therapy and exercise therapy).
Haichen Pharmaceutical: Report for the third quarter of 2024
Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 25% Share Price Plunge Could Signal Some Risk
